Pembrolizumab induced refractory ocular myasthenia gravis: A case report

Immune checkpoint inhibition is a new and promising therapy approved for the treatment of various malignancies. Pembrolizumab is a potent tumour suppressor that acts by upreguLating the immune sys- tem to recognise cancer cells, which May result in disrupted self-tolerance. We describe a case of seronegative ocular myasthenia gravis after treatment with pembrolizumab for metastatic melanoma. Her bilateral ptosis was refractory to conventional treatment, and she remains functionally blind as a result. As the availability and use of immunotherapy continues to rise, awareness of its immune-related adverse effects (irAEs) is crucial for clinicians.